VX-809 (Lumacaftor)
Catalog No.S1565 Synonyms: VRT 826809
Molecular Weight(MW): 452.41
VX-809 (Lumacaftor) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells. Phase 3.
4 Customer Reviews
-
RAF1 and CAMKK1 single siRNA validation in flow cytometry. RAF1 and CAMKK1 single Dharmacon ON-TARGETplus siRNAs with or without VX-809 treatment. Measured surface CFTR fluorescence with a BD Accuri flow cytometer with Intellicyt HTFC. The grayed out region represents VX-809s average surface fluorescence. VX-809 + siRNA significance is shown from VX-809 negative control. Data are shown as mean ± SEM (3−4 replicates). One-way ANOVA with multiple comparison for significant changes from VX-809 neg. ctrl (0 nM) (red P-values). ***P ≤ 0.001; **P ≤ 0.01; *P ≤ 0.05.
Mol Pharm, 2018, 15(3):759-767. VX-809 (Lumacaftor) purchased from Selleck.
△F508CFTR diffusion is increased by different correction mechanisms. A, example trajectories from MDCK cell lines for wtCFTR (black) and △F508CFTR rescued by VX-809 treatment in the absence (red) and presence (blue ) of mCh-CFTR-C. B, summary graph for wtCFTR, r△F508CFTR and CFTR△PDZ diffusion in VX-809-treated and control MDCK cell lines. C, example trajectories for MDCK cells transiently expressing 3FLAG-tagged wtCFTR(black), △F508CFTR rescued by VX-809 (red), CFTR△PDZ ( blue ), and △F508CFTR△PDZ rescued by VX-809 (green). D, summary graph for CFTR dif- fusion in VX-809-treated MDCK transiently transfected with 3FLAG-tagged CFTR constructs. E, example trajectories from MDCK cell lines stably expressing wtCFTR ( left ) and △F508CFTR ( right ) treated with thapsigargin ( black)or CoPo-22 (red) or transiently expressing GFP-GRASP55 (blue ). F, graphs for △F508CFTR ( top ) and wtCFTR (bottom) diffusion in MDCK cell lines treated with thapsigargin or CoPo-22 or transiently expressing GFP-GRASP55. For reference, median and interquartile values for wtCFTR diffusive range are shown by dashed lines(bar 1, top ). G, GFP-GRASP55 is Golgi-localized by immunocytochemical analysis (scale bar, 10 μm). Scale bar in A (500 nm) refers to all trajectories. In panels Band D, statistically significant differences in populations are shown (*, p<0.001). SPT data for MDCK cell lines was derived from 140 –788 trajectories and for transiently transfected MDCK cells from 131–298 trajectories.
J Biol Chem 2012 287, 43630-8. VX-809 (Lumacaftor) purchased from Selleck.
-
VX809 inceases the expression of DF508 CFTR in oocytes. Oocytes injected with DF508 CFTR and b-adrenergic receptor RNAs were incubated at 17oC for 3 days with and without 5 μM VX809. The conductance at the reversal potential (gCl at Vm = Erev) was assayed using two-electrode-voltage clamp. Oocytes were placed in experimental chambers and perfused with standard Frog Ringer's at room temperature where the conductance was monitored as a function of time. The conductance was near zero before stimulation using a cocktail containing 10 μM isoproterenol and 1 μM 3-isobutyl-1-methylxanthine (hatched bar). At steady state, conductance of oocytes treated with 5 μM VX809 ("x" symbols in panel A and white bar in panel B) was significantly larger than that of untreated oocytes ("+" symbols in panel A and black bar in panel B). Towards the end of the experiments, oocytes were exposed to 10 μM CFTR-172 to verify that the conductance was due to CFTR chloride channels.
Xuehong Liu of Oregon Health & Science University. VX-809 (Lumacaftor) purchased from Selleck.
Figure 7. Using chamber experiments demonstrating that TGF- β1 inhibits functional rescue of △ F508-CFTR in CF-HBE cells. Representative recordings ( A&B) demonstrating that VX-809 and CF-106951 partially rescued the CFTRinh -172 sensitive I sc compared to vehicle control (Vehicle). VX-809 (10 μM), CF-106951 (10 μM) or vehicle control (DMSO) was added to the basolateral medium for 24 h. The final concentration of DMSO was ,0.1%. Experiments were repeated at least 3 times in CF-HBE cells from 3 different donors. In subsequent experiments, corrector VX-809 ( C&D) or CF-106951 ( E&F ) was used for 24 h to rescue the CFTRinh-172 sensitive Isc. Subsequently, TGF- β1 (15 ng/ml) or vehicle control (CTRL) was added with fresh VX-809 or CF-106951 to the basolateral medium for 24 h. Monolayers were bathed in Ringer’s solution in the presence of amiloride (10 μM). TGF-β1 decreased the CFTRinh-172 sensitive Isc rescued by either VX-809 or CF-106951.
VX-809 (Lumacaftor) purchased from Selleck.
Purity & Quality Control
Choose Selective CFTR Inhibitors
Biological Activity
| Description | VX-809 (Lumacaftor) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM in fisher rat thyroid cells. Phase 3. | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Features | Higher specificity and efficacy relative to other CFTR defect drugs. | ||||||||||||||||
| Targets |
|
||||||||||||||||
| In vitro |
VX-809 acts at the level of the ER to allow a fraction of the F508del-CFTR to adopt a properly folded form, to exit the ER and mobilize to the cell surface for normal functioning. In Fischer rat thyroid (FRT) cells expressing F508del-CFTR, VX-809 treatment significantly improves F508del-CFTR maturation by 7.1 fold with an EC50 of 0.1 μM, and enhances F508del-CFTR-mediated chloride transport by approximately 5 fold with EC50 of 0.5 μM, while VRT-768 has higher EC50 values of 7.9 μM and 16 μM, respectively. In HEK-293 cells expressing F508del-CFTR, VX-809 (3 μM) treatment increases F508del-CFTR exit from the ER by 6 fold, reaching levels comparable to 34% of CFTR. In primary human bronchial epithelial (HBE) cells with F508del-CFTR mutation, VX-809 increases CFTR maturation and enhances chloride secretion with EC50 of 350 nM and 81 nM, respectively, more efficacious than Corr-4a and VRT-325. F508del-CFTR corrected by VX-809 exhibits single-channel open probability of 0.39 similar to normal CFTR of 0.40. Unlike VX-770, VX-809 is not a CFTR potentiator, as acute addition of VX-809 has no effect on F508del-CFTR function. In contrast to VRT-325 and Corr-4a, VX-809 does not improve the processing of the normal or mutant forms of hERG or P-gp, as well as other disease-causing mislocalized proteins, including α1-antitrypsin Z mutant (E342K-α1-AT) or N370S-β-glucosidase, suggesting that VX-809 is specific for CFTR. VX-809 in combination with VRT-325 or Corr-4a has additive effect on CFTR-mediated chloride transport in cultured F508del-HBE. [1] |
||||||||||||||||
| Cell Data |
|
Protocol
| Kinase Assay:[1] |
+ Expand
F508del-CFTR maturation: Fischer rat thyroid (FRT) cells stably expressing F508del-CFTR are treated with increasing concentrations of VX-809 for 48 hours. After incubation, cells are harvested in ice-cold D-PBS solution (without calcium and magnesium) and pelleted at 1,000 × g at 4 °C. Cell pellets are lysed in 1% Nonidet P-40, 0.5% sodium deoxycholate, 200 mM NaCl, 10 mM Tris, pH 7.8, and 1 mM EDTA plus protease inhibitor mixture (1:250) for 30 minutes on ice. Lysates are spun for 10 minutes at 10,000 × g at 4 °C to pellet nuclei and insoluble material. Approximately 12 μg total protein is heated in Laemmli buffer with 5% β-mercaptoethanol at 37 °C for 5 minutes and loaded onto a 3% to 8% Tris-acetate gel. The gel is transferred to nitrocellulose and processed for Western blotting by using monoclonal CFTR antibody or polyclonal to GAPDH. Blots are developed by enhanced chemiluminescence. Quantification of the relative amounts of bands C and GAPDH is performed by using NIH ImageJ analysis of scanned films. |
|---|---|
| Cell Research:[1] |
+ Expand
|
Solubility (25°C)
| In vitro | DMSO | 90 mg/mL (198.93 mM) |
|---|---|---|
| Ethanol | 6 mg/mL (13.26 mM) | |
| Water | Insoluble | |
| In vivo | Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing. |
30 mg/mL |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 452.41 |
|---|---|
| Formula | C24H18F2N2O5 |
| CAS No. | 936727-05-8 |
| Storage | powder |
| in solvent | |
| Synonyms | VRT 826809 |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02653027 | Withdrawn | Diabetes|Cystic Fibrosis | Massachusetts General Hospital | January 1 2018 | Not Applicable |
| NCT02653027 | Withdrawn | Diabetes|Cystic Fibrosis | Massachusetts General Hospital | January 1 2018 | Not Applicable |
| NCT03125395 | Active not recruiting | Cystic Fibrosis | Vertex Pharmaceuticals Incorporated | May 12 2017 | Phase 3 |
| NCT03125395 | Active not recruiting | Cystic Fibrosis | Vertex Pharmaceuticals Incorporated | May 12 2017 | Phase 3 |
| NCT02858843 | Terminated | Cystic Fibrosis|Diabetes | Massachusetts General Hospital | August 1 2016 | Not Applicable |
| NCT02858843 | Terminated | Cystic Fibrosis|Diabetes | Massachusetts General Hospital | August 1 2016 | Not Applicable |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
